Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Neuraxis to $13 from $8 and keeps a Buy rating on the shares after Q1 results, which exceeded expectations with $1.0M in revenue vs. $0.9M for the Street and a narrower-than-expected net loss. While no 2026 guidance was provided, management's commentary on early 2026 trends was notably positive and ahead of the firm's prior assumptions, driving meaningful estimate increases.
